|
1
|
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
|
Ophthalmology
|
2010
|
10.28
|
|
2
|
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
|
N Engl J Med
|
2015
|
7.08
|
|
3
|
Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema.
|
Ophthalmology
|
2006
|
5.79
|
|
4
|
Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
|
Ophthalmology
|
2011
|
4.15
|
|
5
|
Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema.
|
Arch Ophthalmol
|
2007
|
3.18
|
|
6
|
Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema.
|
Arch Ophthalmol
|
2009
|
2.84
|
|
7
|
Visual acuity as an outcome measure in clinical trials of retinal diseases.
|
Ophthalmology
|
2007
|
2.69
|
|
8
|
Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.
|
Ophthalmology
|
2012
|
2.68
|
|
9
|
Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema.
|
Ophthalmology
|
2007
|
2.58
|
|
10
|
Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.
|
Arch Ophthalmol
|
2009
|
2.06
|
|
11
|
Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction.
|
Ophthalmology
|
2010
|
2.02
|
|
12
|
RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
|
Retina
|
2015
|
1.99
|
|
13
|
Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy.
|
Am J Ophthalmol
|
2008
|
1.87
|
|
14
|
Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings.
|
Arch Ophthalmol
|
2009
|
1.72
|
|
15
|
Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema.
|
Ophthalmology
|
2008
|
1.60
|
|
16
|
Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation.
|
Retina
|
2011
|
1.53
|
|
17
|
Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema.
|
Ophthalmology
|
2011
|
1.52
|
|
18
|
Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema.
|
Invest Ophthalmol Vis Sci
|
2008
|
1.36
|
|
19
|
A proposed method of logarithmic transformation of optical coherence tomography data for use in clinical research.
|
Ophthalmology
|
2010
|
1.34
|
|
20
|
Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography.
|
Invest Ophthalmol Vis Sci
|
2012
|
1.17
|
|
21
|
The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials.
|
Am J Ophthalmol
|
2007
|
1.15
|
|
22
|
Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation.
|
Arch Ophthalmol
|
2009
|
1.13
|
|
23
|
Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema.
|
Ophthalmology
|
2010
|
1.13
|
|
24
|
Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema.
|
Arch Ophthalmol
|
2006
|
1.05
|
|
25
|
Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics.
|
Arch Ophthalmol
|
2012
|
1.01
|
|
26
|
Visual acuity testing using autorefraction or pinhole occluder compared with a manual protocol refraction in individuals with diabetes.
|
Ophthalmology
|
2010
|
0.94
|
|
27
|
Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema.
|
JAMA Ophthalmol
|
2013
|
0.90
|
|
28
|
Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus.
|
Invest Ophthalmol Vis Sci
|
2011
|
0.89
|
|
29
|
Ocular side effects associated with peribulbar injections of triamcinolone acetonide for diabetic macular edema.
|
Retina
|
2011
|
0.88
|
|
30
|
Green or yellow laser treatment for diabetic macular edema: exploratory assessment within the Diabetic Retinopathy Clinical Research Network.
|
Retina
|
2013
|
0.81
|
|
31
|
Topical nepafenec in eyes with noncentral diabetic macular edema.
|
Retina
|
2015
|
0.80
|
|
32
|
Evaluation of visual acuity measurements after autorefraction vs manual refraction in eyes with and without diabetic macular edema.
|
Arch Ophthalmol
|
2011
|
0.79
|
|
33
|
Effects of dilation on electronic-ETDRS visual acuity in diabetic patients.
|
Invest Ophthalmol Vis Sci
|
2008
|
0.75
|
|
34
|
Targeting the Effect of VEGF in Diabetic Macular Edema.
|
N Engl J Med
|
2015
|
0.75
|